Suche
Filter by content type
Filter by content year
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
Oktober 22, 2025 - … development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s … of innovative and transformative investigational mRNA-based cancer immunotherapies for patients in need. With the … strategy, which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig …
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
September 23, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Reaches Agreement to Receive a Non-exclusive License for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent Litigation with CureVac and GSK
August 8, 2025 - … Agreement to Receive a Non-exclusive License for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent … Agreement to Receive a Non-exclusive License for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent … Agreement to Receive a Non-exclusive License for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent …
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
August 4, 2025 - … programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a … uncertainties. Although the Company’s approach to revenue recognition is based on facts and circumstances known to the … uncertainties. Although the Company’s approach to revenue recognition is based on facts and circumstances known to the …
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response with their LP.8.1-adapted COVID-19 Vaccine 2025-2026 Formula
September 8, 2025 - … data. COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were … from the BNT162 program, including a potential variant-based, higher dose, or bivalent vaccine, and if obtained, … future annual boosters or re-vaccinations or new variant-based vaccines or combination vaccines; the risk that we may …
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
August 27, 2025 - … for severe outcomes from COVID-19. 2 The FDA approval is based on the cumulative body of evidence supporting the … COVID-19 vaccines. 3 The LP.8.1 sublineage selection is based on guidance from the FDA, which stated that LP.8.1 is the preferred sublineage of a monovalent JN.1-lineage-based COVID-19 vaccine for use in the U.S. beginning in fall …
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
September 8, 2025 - … which makes it more challenging to treat. 1,2 Platinum-based chemotherapy combined with etoposide chemotherapy has … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
BioNTech and DualityBio Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer
September 5, 2025 - … who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of progression … to the approved ADC trastuzumab emtansine (T-DM1). Based on the results from the interim analysis which were … is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which was built from DualityBio’s …
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Juli 25, 2025 - … individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task … following the EC decision. The CHMP’s recommendation is based on the cumulative body of evidence previously submitted … needs. The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were …
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
Juli 21, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
